Organon & Co (MIL:1OGN)
€ 14.35 0 (0%) Market Cap: 3.72 Bil Enterprise Value: 11.38 Bil PE Ratio: 2.99 PB Ratio: 7.87 GF Score: 45/100

Organon & Co at Morgan Stanley Global Healthcare Conference (Fireside Chat) Transcript

Sep 13, 2021 / 01:30PM GMT
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Thanks for joining us again for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Very pleased to have Organon with us for the next session.

I need to read a quick disclosure statement before we get started. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures are seen on Morgan Stanley public website at morganstanley.com/researchdisclosures.

And very pleased to have from Organon, Kevin Ali, the CEO; and Matt Walsh, the CFO.

Questions & Answers

Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Kevin, I thought maybe just to start us off, since obviously, people are familiar with the company because of the spin from Merck, but may not be as familiar with the focus of the company and the key products. Maybe we could just take a minute or 2 to walk through what the vision is for the company and how you're thinking about the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot